How can we mitigate adverse immune responses to nanoparticles?
Several strategies can be employed to mitigate adverse immune responses. These include optimizing nanoparticle size, shape, and surface properties to reduce immunogenicity. Surface modifications, such as PEGylation, can help avoid recognition by the immune system. Additionally, preclinical testing and biocompatibility studies are essential to identify and address potential immune-related issues before clinical application.
